nephrogenic systemic fibrosis


Also found in: Acronyms, Wikipedia.

nephrogenic systemic fibrosis

A rare condition linked to gadolinium-based MRI contrast solutions—in particular Omniscan and OptiMARK, which have a linear non-ionic structure and more likely to release Gd3+ to tissue—characterised by fibrosis of skin, joints, eyes and internal organs, resulting in scleromyxedema/papular mucinosis-like histologic appearance, limitation of joint movement, kidney failure and, in extreme cases, systemic fibrosis affecting the lungs, heart and liver.
 
Prevention
Some protection may be provided by diethylene-triaminepentaacetic acid.
Mentioned in ?
References in periodicals archive ?
Nephrogenic systemic fibrosis and gadolinium-based contrast media: Updated ESUR Contrast Medium Safety Committee guidelines.
Nephrogenic systemic fibrosis manifests as rapidly progressive fibrosis characterized by the deposition of [CD34.
Nephrogenic systemic fibrosis is an emerging disease principally affecting individuals with advanced chronic renal disease.
Recognizing the broader concept of a systemic process, the disease was rechristened nephrogenic systemic fibrosis (NSF).
Patients with reduced renal function are at risk of developing contrast-induced nephrotoxicity (CIN) following a contrast-enhanced computed tomography (CT) examination with an iodinated contrast agent (1) and at risk of developing nephrogenic systemic fibrosis (NSF) after a contrast-enhanced magnetic resonance imaging (MRI) examination with an extracellular gadolinium-based contrast agent.
The Food and Drug Administration has requested that a boxed warning explaining the increased risk of nephrogenic systemic fibrosis in patients with renal insufficiency be added to the labels of gadolinium-based contrast agents, according to an alert posted on the agency's MedWatch Web site.
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with:
Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.
In addition to the potential for allergic reactions, some patients, particularly those with decreased renal function, face the risk of contrast-induced nephropathy (CIN) and nephrogenic systemic fibrosis (NSF).
Gadolinium-based contrast agents, when given to patients with renal disease, have been associated with a rare, potentially fatal, sclerodermalike skin disease called nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy.
Food and Drug Administration's (FDA) announcement requiring safety-related label changes for all gadolinium-based contrast agents to highlight the rare and potentially fatal condition known as nephrogenic systemic fibrosis (NSF).